{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:36:14Z","timestamp":1782207374208,"version":"3.54.5"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["metabolismjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.metabol.2024.156000","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T21:34:18Z","timestamp":1723498458000},"page":"156000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Steatotic liver disease in the context of hematological malignancies and anti-neoplastic chemotherapy"],"prefix":"10.1016","volume":"160","author":[{"given":"Charalampos G.","family":"Pontikoglou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodosios D.","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelos","family":"Matheakakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen A.","family":"Papadaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.metabol.2024.156000_bb0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology (Baltimore, Md)."},{"issue":"1","key":"10.1016\/j.metabol.2024.156000_bb0010","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.metabol.2024.156000_bb0015","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.metabol.2024.156000_bb0020","first-page":"17","volume":"31","author":"Huh","year":"2022","journal-title":"Recent epidemiology and risk factors of nonalcoholic fatty liver disease"},{"issue":"6","key":"10.1016\/j.metabol.2024.156000_bb0025","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology (Baltimore, Md)."},{"issue":"4","key":"10.1016\/j.metabol.2024.156000_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156000_bb0035","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12902-021-00789-4","article-title":"Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"21","author":"Salari","year":"2021","journal-title":"BMC Endocr Disord"},{"issue":"29","key":"10.1016\/j.metabol.2024.156000_bb0040","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000029958","article-title":"Association of sorting and assembly machinery component 50 homolog gene polymorphisms with nonalcoholic fatty liver disease susceptibility","volume":"101","author":"Qiao","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"10.1016\/j.metabol.2024.156000_bb0045","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.dld.2015.08.004","article-title":"Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups","volume":"47","author":"Lonardo","year":"2015","journal-title":"Dig Liver Dis"},{"issue":"5","key":"10.1016\/j.metabol.2024.156000_bb0050","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology (Baltimore, Md)."},{"issue":"14","key":"10.1016\/j.metabol.2024.156000_bb0055","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.metabol.2024.156000_bb0060","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.metabol.2024.156000_bb0065","article-title":"Metabolic-associated fatty liver disease (MAFLD), diabetes, and cardiovascular disease: associations with fructose metabolism and gut microbiota","volume":"14","author":"Dro\u017cd\u017c","year":"2021"},{"issue":"3","key":"10.1016\/j.metabol.2024.156000_bb0070","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.metabol.2024.156000_bb0075","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jhep.2017.12.012","article-title":"Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: an observational cohort study","volume":"68","author":"Lee","year":"2018","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156000_bb0080","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.eprac.2022.10.007","article-title":"A meta-analysis on associated risk of mortality in nonalcoholic fatty liver disease","volume":"29","author":"Fu","year":"2023","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.metabol.2024.156000_bb0085","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2306192","article-title":"The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis","volume":"56","author":"Lv","year":"2024","journal-title":"Ann Med"},{"issue":"8","key":"10.1016\/j.metabol.2024.156000_bb0090","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","article-title":"Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review","volume":"73","author":"Stahl","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.metabol.2024.156000_bb0095","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications","volume":"65","author":"Francque","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.156000_bb0100","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.athplu.2024.01.004","article-title":"Executive summary of the hellenic atherosclerosis society guidelines for the diagnosis and treatment of dyslipidemias - 2023","volume":"55","author":"Katsiki","year":"2024","journal-title":"Atherosclerosis Plus"},{"key":"10.1016\/j.metabol.2024.156000_bb0105","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1476-511X-13-100","article-title":"Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile","volume":"13","author":"Corey","year":"2014","journal-title":"Lipids Health Dis"},{"issue":"11","key":"10.1016\/j.metabol.2024.156000_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241993","article-title":"Association of small, dense LDL-cholesterol concentration and lipoprotein particle characteristics with coronary heart disease: a systematic review and meta-analysis","volume":"15","author":"Liou","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.metabol.2024.156000_bb0115","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2331460","article-title":"Breaking the barriers: the role of gut homeostasis in metabolic-associated steatotic liver disease (MASLD)","volume":"16","author":"Bened\u00e9-Ubieto","year":"2024","journal-title":"Gut Microbes"},{"issue":"6","key":"10.1016\/j.metabol.2024.156000_bb0120","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/hep.23535","article-title":"Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease","volume":"51","author":"Abdelmalek","year":"2010","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"4","key":"10.1016\/j.metabol.2024.156000_bb0125","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/liv.15844","article-title":"Cardiac remodelling in non-alcoholic fatty liver disease in the general population","volume":"44","author":"Kostka","year":"2024","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.metabol.2024.156000_bb0130","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.metabol.2024.156000_bb0135","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.cgh.2022.04.014","article-title":"Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"21","author":"Ng","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.metabol.2024.156000_bb0140","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology (Baltimore, Md)."},{"issue":"6","key":"10.1016\/j.metabol.2024.156000_bb0145","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/hep.30946","article-title":"The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH","volume":"70","author":"Loomba","year":"2019","journal-title":"Hepatology (Baltimore, Md)."},{"issue":"2","key":"10.1016\/j.metabol.2024.156000_bb0150","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S2468-1253(23)00275-3","article-title":"Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease","volume":"9","author":"Thomas","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.metabol.2024.156000_bb0155","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management. A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.metabol.2024.156000_bb0160","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11901-019-00499-5","article-title":"Extrahepatic malignancies in nonalcoholic fatty liver disease","volume":"18","author":"Ahmed","year":"2019","journal-title":"Current Hepatology Reports"},{"issue":"4","key":"10.1016\/j.metabol.2024.156000_bb0165","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.metabol.2024.156000_bb0170","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2019.08.018","article-title":"The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - a longitudinal cohort study","volume":"71","author":"Allen","year":"2019","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.metabol.2024.156000_bb0175","first-page":"459","article-title":"Increased risk of colorectal polyps in patients with non-alcoholic fatty liver disease undergoing liver transplant evaluation","volume":"6","author":"Bhatt","year":"2015","journal-title":"Journal of Gastrointestinal Oncology"},{"issue":"26","key":"10.1016\/j.metabol.2024.156000_bb0180","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.metabol.2024.156000_bb0185","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.metabol.2024.156000_bb0190","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.metabol.2024.156000_bb0195","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1182\/bloodadvances.2020001582","article-title":"High prevalence of clonal hematopoiesis in the blood and bone marrow of healthy volunteers","volume":"4","author":"Guermouche","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.metabol.2024.156000_bb0200","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/MOH.0000000000000675","article-title":"Clonal hematopoiesis and myeloid malignancies: clonal dynamics and clinical implications","volume":"28","author":"Elena","year":"2021","journal-title":"Curr Opin Hematol"},{"issue":"10","key":"10.1016\/j.metabol.2024.156000_bb0205","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2018-10-844654","article-title":"The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes","volume":"133","author":"Sallman","year":"2019","journal-title":"Blood"},{"issue":"7958","key":"10.1016\/j.metabol.2024.156000_bb0210","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41586-023-05857-4","article-title":"Clonal haematopoiesis and risk of chronic liver disease","volume":"616","author":"Wong","year":"2023","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.metabol.2024.156000_bb0215","first-page":"193","article-title":"The impact of obesity-induced inflammation on clonal hematopoiesis","volume":"31","author":"Pasupuleti","year":"2024","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156000_bb0220","first-page":"2070","volume":"14","author":"Zioni","year":"2023","journal-title":"Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis"},{"issue":"6","key":"10.1016\/j.metabol.2024.156000_bb0225","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s00277-018-3565-5","article-title":"Primary hepatic marginal B cell lymphoma of mucosa-associated lymphoid tissue (MALT) and non-alcoholic steatohepatitis (NASH): more than a coincidence?","volume":"98","author":"Haefliger","year":"2019","journal-title":"Ann Hematol"},{"issue":"3\u20134","key":"10.1016\/j.metabol.2024.156000_bb0230","first-page":"293","article-title":"Primary non-Hodgkin\u2019s lymphoma of the liver","volume":"29","author":"Lei","year":"1998","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.metabol.2024.156000_bb0235","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2002-04-1279","article-title":"Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue","volume":"101","author":"Zucca","year":"2003","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.metabol.2024.156000_bb0240","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1182\/blood-2015-12-624304","article-title":"The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance","volume":"127","author":"Zucca","year":"2016","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.metabol.2024.156000_bb0245","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015034","article-title":"Primary hepatic mucosa-associated lymphoid tissue lymphoma: a case report and literature review","volume":"98","author":"Xie","year":"2019","journal-title":"Medicine"},{"issue":"11","key":"10.1016\/j.metabol.2024.156000_bb0250","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.dld.2020.04.024","article-title":"A long-term follow-up of primary hepatic mucosa-associated lymphoid tissue lymphoma","volume":"52","author":"Chen","year":"2020","journal-title":"Dig Liver Dis"},{"issue":"1","key":"10.1016\/j.metabol.2024.156000_bb0255","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00042737-199701000-00020","article-title":"Primary hepatic lymphoma in a man with chronic hepatitis C","volume":"9","author":"Clarke","year":"1997","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.metabol.2024.156000_bb0260","first-page":"250","article-title":"Primary hepatic marginal zone lymphoma in a patient with chronic hepatitis C","volume":"11","author":"Gherlan","year":"2016","journal-title":"Maedica"},{"key":"10.1016\/j.metabol.2024.156000_bb0265","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9183717","article-title":"Primary hepatic lymphoma mimicking a hepatocellular carcinoma in a cirrhotic patient: case report and systematic review of the literature","volume":"2018","author":"Bohlok","year":"2018","journal-title":"Case Reports in Surgery"},{"issue":"4","key":"10.1016\/j.metabol.2024.156000_bb0270","first-page":"404","article-title":"Primary hepatic low-grade B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) associated with primary biliary cirrhosis","volume":"11","author":"Prabhu","year":"1998","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156000_bb0275","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.leukres.2009.07.031","article-title":"Primary hepatic MALT lymphoma associated with primary biliary cirrhosis","volume":"34","author":"Nakayama","year":"2010","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.metabol.2024.156000_bb0280","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4254\/wjh.v9.i3.155","article-title":"Primary mucosa-associated lymphoid tissue lymphoma of the liver: a report of two cases and review of the literature","volume":"9","author":"Obiorah","year":"2017","journal-title":"World J Hepatol"},{"issue":"8","key":"10.1016\/j.metabol.2024.156000_bb0285","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3748\/wjg.v18.i8.727","article-title":"Role of cytokines and chemokines in non-alcoholic fatty liver disease","volume":"18","author":"Braunersreuther","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"10","key":"10.1016\/j.metabol.2024.156000_bb0290","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.it.2008.07.003","article-title":"New insights into NF-\u03baB regulation and function","volume":"29","author":"Sun","year":"2008","journal-title":"Trends Immunol"},{"key":"10.1016\/j.metabol.2024.156000_bb0295","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.semcancer.2016.07.003","article-title":"MALT lymphoma: a paradigm of NF-\u03baB dysregulation","volume":"39","author":"Du","year":"2016","journal-title":"Semin Cancer Biol"},{"issue":"8","key":"10.1016\/j.metabol.2024.156000_bb0300","doi-asserted-by":"crossref","first-page":"838","DOI":"10.2169\/internalmedicine.44.838","article-title":"Type 2 diabetes mellitus complicated with smoldering myeloma and non-alcoholic steatohepatitis","volume":"44","author":"Nakahara","year":"2005","journal-title":"Int Med (Tokyo, Japan)"},{"issue":"14","key":"10.1016\/j.metabol.2024.156000_bb0305","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.2169\/internalmedicine.0092-17","article-title":"A patient with non-alcoholic steatohepatitis complicated by multiple myeloma","volume":"57","author":"Akashi","year":"2018","journal-title":"Int Med (Tokyo, Japan)"},{"key":"10.1016\/j.metabol.2024.156000_bb0310","series-title":"American Society of Clinical Oncology Educational Book American Society of Clinical Oncology Annual Meeting","first-page":"e418","article-title":"Updated diagnostic criteria and staging system for multiple myeloma","volume":"35","author":"Rajkumar","year":"2016"},{"issue":"25","key":"10.1016\/j.metabol.2024.156000_bb0315","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"48","key":"10.1016\/j.metabol.2024.156000_bb0320","doi-asserted-by":"crossref","first-page":"18070","DOI":"10.3748\/wjg.v20.i48.18070","article-title":"Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease","volume":"20","author":"Stojsavljevi\u0107","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.metabol.2024.156000_bb0325","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1852517","article-title":"Inflammatory and anti-inflammatory equilibrium, proliferative and antiproliferative balance: the role of cytokines in multiple myeloma","volume":"2017","author":"Musolino","year":"2017","journal-title":"Mediators Inflamm"},{"issue":"9","key":"10.1016\/j.metabol.2024.156000_bb0330","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41408-022-00719-0","article-title":"Smoldering multiple myeloma current treatment algorithms","volume":"12","author":"Rajkumar","year":"2022","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.metabol.2024.156000_bb0335","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1053\/j.gastro.2009.06.051","article-title":"Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease","volume":"137","author":"Syn","year":"2009","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.metabol.2024.156000_bb0340","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.23998","article-title":"Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis","volume":"53","author":"Syn","year":"2011","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.metabol.2024.156000_bb0345","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clinbiochem.2018.07.003","article-title":"The multiple functions and mechanisms of osteopontin","volume":"59","author":"Icer","year":"2018","journal-title":"Clin Biochem"},{"issue":"3","key":"10.1016\/j.metabol.2024.156000_bb0350","volume":"13","author":"Mart\u00edn-M\u00e1rquez","year":"2023","journal-title":"Osteopontin: a bone-derived protein involved in rheumatoid arthritis and osteoarthritis immunopathology"},{"issue":"2","key":"10.1016\/j.metabol.2024.156000_bb0355","first-page":"174","article-title":"Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma","volume":"89","author":"Standal","year":"2004","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.metabol.2024.156000_bb0360","doi-asserted-by":"crossref","DOI":"10.1111\/ecc.12761","article-title":"Mechanisms of bone destruction in multiple myeloma","volume":"26","author":"Terpos","year":"2017","journal-title":"Eur J Cancer Care"},{"issue":"3","key":"10.1016\/j.metabol.2024.156000_bb0365","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.0902-4441.2003.00203.x","article-title":"Association of non-alcoholic steatohepatitis (NASH) with chronic neutrophilic leukemia","volume":"72","author":"Yoshida","year":"2004","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.metabol.2024.156000_bb0370","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/ajh.27321","article-title":"Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management","volume":"99","author":"Szuber","year":"2024","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.metabol.2024.156000_bb0375","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/1097-0142(20000801)89:3<551::AID-CNCR10>3.0.CO;2-E","article-title":"Hyperfunction of neutrophils in a patient with BCR\/ABL negative chronic myeloid leukemia","volume":"89","author":"Watari","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.metabol.2024.156000_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.603926","article-title":"Non-alcoholic steatohepatitis: a review of its mechanism, models and medical treatments","volume":"11","author":"Peng","year":"2020","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.metabol.2024.156000_bb0385","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1136\/gutjnl-2022-328887","article-title":"Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of extrahepatic cancer","volume":"72","author":"Roderburg","year":"2023","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.metabol.2024.156000_bb0390","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12944-020-01288-6","article-title":"Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis","volume":"19","author":"Liu","year":"2020","journal-title":"Lipids Health Dis"},{"issue":"3","key":"10.1016\/j.metabol.2024.156000_bb0395","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/hepr.13980","article-title":"Causal association of nonalcoholic fatty liver disease with 22 extrahepatic cancers: a Mendelian randomization study","volume":"54","author":"Xie","year":"2024","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.metabol.2024.156000_bb0400","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41467-019-14156-4","article-title":"A robust and efficient method for Mendelian randomization with hundreds of genetic variants","volume":"11","author":"Burgess","year":"2020","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.metabol.2024.156000_bb0405","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.metabol.2024.156000_bb0410","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.metabol.2024.156000_bb0415","first-page":"76","article-title":"Non-alcoholic fatty liver disease: growing burden, adverse outcomes and associations","volume":"8","author":"Kumar","year":"2020","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.metabol.2024.156000_bb0420","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/liv.15195","article-title":"Risk of hepatic and extrahepatic cancer in NAFLD: a population-based cohort study","volume":"42","author":"Bj\u00f6rkstr\u00f6m","year":"2022","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.metabol.2024.156000_bb0425","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-0034-1375960","article-title":"Drug-induced hepatic steatosis","volume":"34","author":"Amacher","year":"2014","journal-title":"Semin Liver Dis"},{"issue":"1","key":"10.1016\/j.metabol.2024.156000_bb0430","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jhep.2017.02.031","article-title":"Reversibility of chemotherapy-related liver injury","volume":"67","author":"Vigano","year":"2017","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.metabol.2024.156000_bb0435","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/bjs.10572","article-title":"Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases","volume":"104","author":"Zhao","year":"2017","journal-title":"Br J Surg"},{"issue":"3","key":"10.1016\/j.metabol.2024.156000_bb0445","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S1470-2045(09)70064-6","article-title":"Management of chemotherapy associated hepatotoxicity in colorectal liver metastases","volume":"10","author":"Chun","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.metabol.2024.156000_bb0450","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s10120-019-01009-8","article-title":"Risk factors for nonalcoholic fatty liver disease after gastrectomy for gastric cancer","volume":"23","author":"Kouzu","year":"2020","journal-title":"Gastric Cancer"},{"issue":"13","key":"10.1016\/j.metabol.2024.156000_bb0455","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1245\/s10434-012-2438-8","article-title":"Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis","volume":"19","author":"Robinson","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"14","key":"10.1016\/j.metabol.2024.156000_bb0460","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1002\/cncr.24374","article-title":"The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer","volume":"115","author":"Saphner","year":"2009","journal-title":"Cancer"},{"issue":"7497","key":"10.1016\/j.metabol.2024.156000_bb0465","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1136\/bmj.38391.663287.E0","article-title":"Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial","volume":"330","author":"Bruno","year":"2005","journal-title":"Br Med J"},{"issue":"6","key":"10.1016\/j.metabol.2024.156000_bb0470","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-induced liver injury","volume":"70","author":"Andrade","year":"2019","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.metabol.2024.156000_bb0475","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1472-8206.2008.00608.x","article-title":"Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies","volume":"22","author":"Labbe","year":"2008","journal-title":"Fundam Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156000_bb0480","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.taap.2015.08.022","article-title":"Mechanistic review of drug-induced steatohepatitis","volume":"289","author":"Schumacher","year":"2015","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"10.1016\/j.metabol.2024.156000_bb0485","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.aohep.2019.11.012","article-title":"Chemotherapy-associated steatohepatitis","volume":"19","author":"Meunier","year":"2020","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.metabol.2024.156000_bb0490","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1347402","article-title":"Inflammation as a driver of hematological malignancies","volume":"14","author":"Saluja","year":"2024","journal-title":"Front Oncol"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524002270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524002270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T16:55:10Z","timestamp":1732640110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049524002270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":97,"alternative-id":["S0026049524002270"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156000","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Steatotic liver disease in the context of hematological malignancies and anti-neoplastic chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"156000"}}